Gastric/GE Junction Cancer

[1]  D. Richel,et al.  Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Ashman,et al.  Outcomes of minimally invasive esophagectomy in esophageal cancer after neoadjuvant chemoradiotherapy. , 2014, The Annals of thoracic surgery.

[3]  C. Fuchs,et al.  Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial , 2014, The Lancet.

[4]  D. Park,et al.  Long-term outcomes of endoscopic submucosal dissection for early gastric cancer: a single-center experience , 2013, Surgical Endoscopy.

[5]  F. Calvo,et al.  Postchemoradiation Resected Locally Advanced Esophageal and Gastroesophageal Junction Carcinoma: Long-Term Outcome With or Without Intraoperative Radiotherapy , 2013, Annals of Surgical Oncology.

[6]  F. Calvo,et al.  Intraoperative radiotherapy for the treatment of resectable locally advanced gastric adenocarcinoma: topography of locoregional recurrences and long-term outcomes , 2013, Clinical and Translational Oncology.

[7]  A. McKenna,et al.  Exome and whole genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity , 2013, Nature Genetics.

[8]  M. Meyerson,et al.  Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. , 2012, Cancer research.

[9]  J. Ajani,et al.  Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  E W Steyerberg,et al.  Preoperative chemoradiotherapy for esophageal or junctional cancer. , 2012, The New England journal of medicine.

[11]  Joon-Oh Park,et al.  Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Y. Ohashi,et al.  Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  D. Fleischer,et al.  An early experience using the technique of transoral OrVil EEA stapler for minimally invasive transthoracic esophagectomy. , 2011, The Annals of thoracic surgery.

[14]  C. Willett,et al.  Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Pignon,et al.  Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  G. Packham,et al.  Investigating the Nrf2 transcription factor as a regulator of cisplatin resistance in urothelial carcinoma (UC) cells. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  F. Soares,et al.  The influence of CD44v6, TGF-α, COX-2, MMP-7, and MMP-9 on clinical evolution of patients with gastric cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  G. Ezzell,et al.  Trimodality Therapy for Distal Esophageal/Esophagogastric Junction Adenocarcinoma using Three-dimensional Conformal and Intensity Modulated Radiotherapy , 2010 .

[19]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[20]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[21]  Y. Ung,et al.  Adjuvant radiotherapy for gastric cancer: A dosimetric comparison of 3-dimensional conformal radiotherapy, tomotherapy and conventional intensity modulated radiotherapy treatment plans. , 2010, Medical dosimetry : official journal of the American Association of Medical Dosimetrists.

[22]  D. Sargent,et al.  Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. , 2010, JAMA.

[23]  G. Lockwood,et al.  Interfraction and respiratory organ motion during conformal radiotherapy in gastric cancer. , 2010, International journal of radiation oncology, biology, physics.

[24]  L. Gunderson,et al.  Advancements in radiation techniques for gastric cancer. , 2010, The Journal of the National Comprehensive Cancer Network.

[25]  Zhen Wang,et al.  Systematic review of D2 lymphadenectomy versus D2 with para-aortic nodal dissection for advanced gastric cancer. , 2010, World journal of gastroenterology.

[26]  J. McVernon,et al.  Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. , 2010, JAMA.

[27]  B. Corn,et al.  Limited advantages of intensity-modulated radiotherapy over 3D conformal radiation therapy in the adjuvant management of gastric cancer. , 2009, International journal of radiation oncology, biology, physics.

[28]  M. Borad,et al.  Localized gastric or gastroesophageal cancer - chemoradiation is a pertinent component of adjuvant treatment for patients at high risk of relapse. , 2009, Gastrointestinal cancer research : GCR.

[29]  M. Stuschke,et al.  Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  J. Tepper,et al.  Crossroads in the combined-modality management of gastroesophageal junction carcinomas. , 2008, Gastrointestinal cancer research : GCR.

[31]  Charles S Mayo,et al.  Hybrid IMRT for treatment of cancers of the lung and esophagus. , 2008, International journal of radiation oncology, biology, physics.

[32]  Ping Xia,et al.  Can all centers plan intensity-modulated radiotherapy (IMRT) effectively? An external audit of dosimetric comparisons between three-dimensional conformal radiotherapy and IMRT for adjuvant chemoradiation for gastric cancer. , 2008, International journal of radiation oncology, biology, physics.

[33]  D. Sugarbaker,et al.  Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  U. Hopt,et al.  Long-term results after intraoperative radiation therapy for gastric cancer. , 2008, International journal of radiation oncology, biology, physics.

[35]  Alex Kiss,et al.  Stage-Specific Effect of Adjuvant Therapy Following Gastric Cancer Resection: a Population-based Analysis of 4,041 Patients , 2008, Annals of Surgical Oncology.

[36]  A. Norman,et al.  Capecitabine and oxaliplatin for advanced esophagogastric cancer. , 2008, The New England journal of medicine.

[37]  G. Cabibbo,et al.  The impact of radiotherapy on survival in resectable gastric carcinoma: a meta-analysis of literature data. , 2007, Cancer treatment reviews.

[38]  Val Gebski,et al.  Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. , 2007, The Lancet. Oncology.

[39]  J. Ajani,et al.  Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  C. V. D. van de Velde,et al.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. , 2006, The New England journal of medicine.

[41]  A. Norman,et al.  Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: The REAL 2 trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  K. Farrey,et al.  Intensity-modulated radiation therapy in the treatment of gastric cancer: early clinical outcome and dosimetric comparison with conventional techniques. , 2006, The British journal of radiology.

[43]  Joon-Oh Park,et al.  Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer , 2006, Cancer Chemotherapy and Pharmacology.

[44]  Helen H Liu,et al.  Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery. , 2006, International journal of radiation oncology, biology, physics.

[45]  Joon-Oh Park,et al.  An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. , 2005, International journal of radiation oncology, biology, physics.

[46]  I. Choi,et al.  Phase II Study of Low-Dose Docetaxel/Fluorouracil/Cisplatin in Metastatic Gastric Carcinoma , 2005, American journal of clinical oncology.

[47]  J. Ajani,et al.  Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  Y. Bang,et al.  Docetaxel + 5-fluorouracil + cisplatin 3-day combination chemotherapy as a first-line treatment in patients with unresectable gastric cancer. , 2005, Japanese journal of clinical oncology.

[49]  M. Bains,et al.  Patterns of Initial Recurrence in Completely Resected Gastric Adenocarcinoma , 2004, Annals of surgery.

[50]  F. Lohr,et al.  IMRT for postoperative treatment of gastric cancer: covering large target volumes in the upper abdomen: a comparison of a step-and-shoot and an arc therapy approach. , 2004, International journal of radiation oncology, biology, physics.

[51]  W. Foulkes,et al.  Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria , 2004, Journal of Medical Genetics.

[52]  W. Scheithauer,et al.  Effective Combination Chemotherapy with Bimonthly Docetaxel and Cisplatin with or without Hematopoietic Growth Factor Support in Patients with Advanced Gastroesophageal Cancer , 2003, Oncology.

[53]  G. Lockwood,et al.  IMRT for adjuvant radiation in gastric cancer: a preferred plan? , 2003, International journal of radiation oncology, biology, physics.

[54]  F. di Costanzo,et al.  Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[55]  Y. Sakata,et al.  Docetaxel and cisplatin in patients with advanced gastric cancer: results of Japanese phase I/II study , 2002, Gastric Cancer.

[56]  Y. Doki,et al.  Neoadjuvant Chemotherapy followed by Salvage Surgery: Effect on Survival of Patients with Primary Noncurative Gastric Cancer , 2002, World Journal of Surgery.

[57]  W. Scheithauer,et al.  Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancer , 2002, British Journal of Cancer.

[58]  L. Gunderson.  Gastric cancer--patterns of relapse after surgical resection. , 2002, Seminars in radiation oncology.

[59]  J. Tepper,et al.  Radiation treatment parameters in the adjuvant postoperative therapy of gastric cancer. , 2002, Seminars in radiation oncology.

[60]  Christopher Willett,et al.  Gastric surgical adjuvant radiotherapy consensus report: rationale and treatment implementation. , 2002, International journal of radiation oncology, biology, physics.

[61]  Y. Shimada,et al.  Phase I-II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer , 2001 .

[62]  C. Caldas,et al.  Prophylactic total gastrectomy for familial gastric cancer. , 2001, Surgery.

[63]  Scott A. Hundahl,et al.  Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. , 2001, The New England journal of medicine.

[64]  L. Gianni,et al.  Meta-analyses of randomized trials of adjuvant chemotherapy in gastric cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[65]  B. Petersen,et al.  Germline E‐cadherin gene mutations , 2001, Cancer.

[66]  C. Caldas,et al.  Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. , 2001, The New England journal of medicine.

[67]  R. Mazzanti,et al.  Randomized trial of adjuvant chemotherapy versus control after curative resection for gastric cancer: 5-year follow-up , 2001, British Journal of Cancer.

[68]  M. Iannettoni,et al.  Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  V. Schumpelick,et al.  Endoscopic ultrasonography in the preoperative staging of gastric cancer , 2000, Surgical Endoscopy.

[70]  S. Barni,et al.  Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[71]  S. H. Lee,et al.  Frequent somatic mutations of the beta-catenin gene in intestinal-type gastric cancer. , 1999, Cancer research.

[72]  C. Earle,et al.  Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. , 1999, European journal of cancer.

[73]  Teruhiko Yoshida,et al.  Gastric cancers of the microsatellite mutator phenotype display characteristic genetic and clinical features. , 1999, Gastroenterology.

[74]  H. Keizer,et al.  Chemotherapy for operable gastric cancer: results of the Dutch randomised FAMTX trial. The Dutch Gastric Cancer Group (DGCG). , 1999, European journal of cancer.

[75]  D. Gouma,et al.  Extended lymph-node dissection for gastric cancer. , 1999, The New England journal of medicine.

[76]  P. Fayers,et al.  Patient survival after D 1 and D 2 resections for gastric cancer: long-term results of the MRC randomized surgical trial , 1999, British Journal of Cancer.

[77]  W. Yin,et al.  Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC)--report on 370 patients. , 1998, International journal of radiation oncology, biology, physics.

[78]  M. Hou,et al.  Endoscopic ultrasonography for preoperative locoregional staging and assessment of resectability in gastric cancer. , 1998, Clinical imaging.

[79]  T. Chiou,et al.  Phase II study of the modified regimen of etoposide, leucovorin and 5-fluorouracil for patients with advanced gastric cancer. , 1998, Japanese journal of clinical oncology.

[80]  L. Grande,et al.  Randomized trial of adjuvant chemotherapy with mitomycin plus ftorafur versus mitomycin alone in resected locally advanced gastric cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  Hsiu‐Po Wang,et al.  Loss of pS2 Protein Expression Is an Early Event of Intestinal‐type Gastric Cancer , 1998, Japanese journal of cancer research : Gann.

[82]  P. Romestaing,et al.  Intraoperative radiation therapy combined with limited lymph node resection in gastric cancer: an alternative to extended dissection? , 1997, International journal of radiation oncology, biology, physics.

[83]  S. Barni,et al.  Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  J. Roh,et al.  Retrospective comparison of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (modified FAM) combination chemotherapy versus palliative therapy in treatment of advanced gastric cancer. , 1997, American journal of clinical oncology.

[85]  J. García-Foncillas,et al.  Patterns of failure and long‐term results in high‐risk resected gastric cancer treated with postoperative radiotherapy with or without intraoperative electron boost , 1997, Journal of surgical oncology.

[86]  I. Judson,et al.  First demonstration of anti-lymphoma activity of BCL-2 antisense molecule-G3139; Results of phase I/IIA clinical trial , 1997 .

[87]  S. Groshen,et al.  Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy , 1997, Cancer.

[88]  Y. Kajiyama,et al.  Prognostic factors in adenocarcinoma of the gastric cardia: pathologic stage analysis and multivariate regression analysis. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  U. Haglund,et al.  Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[90]  P. Chambon,et al.  Gastric Mucosa Abnormalities and Tumorigenesis in Mice Lacking the pS2 Trefoil Protein , 1996, Science.

[91]  B. Meunier,et al.  Prospective randomized trial comparing Billroth I and Billroth II procedures for carcinoma of the gastric antrum. , 1996, Journal of the American College of Surgeons.

[92]  F. Bozzetti,et al.  Comparing reconstruction with Roux-en-Y to a pouch following total gastrectomy. , 1996, Journal of the American College of Surgeons.

[93]  T. Walsh,et al.  A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. , 1996, The New England journal of medicine.

[94]  E. Tan,et al.  A phase II trial of etoposide, leucovorin and 5-fluorouracil (ELF) in patients with advanced gastric cancer. , 1996, Journal of chemotherapy.

[95]  A. Neugut,et al.  Epidemiology of gastric cancer. , 2006, World journal of gastroenterology.

[96]  S. Semba,et al.  Molecular biological observations in gastric cancer. , 1996, Seminars in oncology.

[97]  J. Ajani,et al.  Laparoscopic staging for gastric cancer. , 1996, Surgery.

[98]  C. Lightdale,et al.  Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[99]  P. Fayers,et al.  Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial , 1996, The Lancet.

[100]  S. Romano,et al.  Adjuvant chemotherapy after gastric resection in node-positive cancer patients: a multicentre randomised study. , 1996, British Journal of Cancer.

[101]  T. Fleming,et al.  Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A southwest oncology group study , 1995, Annals of Surgical Oncology.

[102]  R. Labianca,et al.  Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[103]  H. Stettner,et al.  A 10‐year experience with Japanese‐type radical lymph node dissection for gastric cancer outside of Japan , 1995, Cancer.

[104]  K. Fuchs,et al.  Reconstruction of the food passage after total gastrectomy: Randomized trial , 1995, World Journal of Surgery.

[105]  H. Feußner,et al.  Preoperative chemotherapy for stage III–IV gastric carcinoma: Feasibility, response and outcome after complete resection , 1995, The British journal of surgery.

[106]  G. Hanks,et al.  Treatment of adenocarcinoma of the stomach with resection, intraoperative radiotherapy, and adjuvant external beam radiation: A phase II study from radiation therapy oncology group 85-04 , 1995, Annals of Surgical Oncology.

[107]  T. Lehnert,et al.  Reconstruction after gastrectomy and quality of life , 1995, World Journal of Surgery.

[108]  S. Yoshida,et al.  A 10-year experience of intraoperative radiotherapy for gastric carcinoma and a new surgical method of creating a wider irradiation field for cases of total gastrectomy patients. , 1995, International journal of radiation oncology, biology, physics.

[109]  E. Van Cutsem,et al.  Etoposide, leucovorin and 5-fluorouracil in advanced gastric cancer: a phase II study. , 1995, Anticancer research.

[110]  T. Nakamura,et al.  Hepatocyte growth factor is the most potent endogenous stimulant of rabbit gastric epithelial cell proliferation and migration in primary culture. , 1995, The Journal of clinical investigation.

[111]  D. Levison,et al.  Pathological prognostic factors in the second British Stomach Cancer Group trial of adjuvant therapy in resectable gastric cancer. , 1995, British Journal of Cancer.

[112]  J. Hermans,et al.  Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients , 1995, The Lancet.

[113]  S. Pyrhönen,et al.  Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. , 1995, British Journal of Cancer.

[114]  D. Noh,et al.  Significant prognostic factors by multivariate analysis of 3926 gastric cancer patients , 1994, World Journal of Surgery.

[115]  E. G. Hahn,et al.  Coated and uncoated self-expanding metal stents for malignant stenosis in the upper GI tract: preliminary clinical experiences with Wallstents. , 1994, The American journal of gastroenterology.

[116]  T. Hickish,et al.  A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[117]  D. Kelsen.  The use of chemotherapy in the treatment of advanced gastric and pancreas cancer. , 1994, Seminars in oncology.

[118]  A. Li,et al.  A Prospective Randomized Trial Comparing R1 Subtotal Gastrectomy with R3 Total Gastrectomy for Antral Cancer , 1994, Annals of surgery.

[119]  W. Allum,et al.  The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up , 1994, The Lancet.

[120]  M. Buyse,et al.  Meta-analyses need time, collaboration, and funding. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[121]  J. Pignon,et al.  Meta-analysis of adjuvant chemotherapy in gastric cancer: a critical reappraisal. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[122]  G. Fleuren,et al.  Factors influencing noncompliance and contamination in a randomized trial of “Western” (r1) versus “Japanese” (r2) type surgery in gastric cancer , 1994, Cancer.

[123]  G. Fleuren,et al.  Evaluation of the extent of lymphadenectomy in a randomized trial of Western- versus Japanese-type surgery in gastric cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[124]  R. Buras,et al.  Intensive preoperative radiotherapy with local hyperthermia for the treatment of gastric carcinoma. , 1994, Surgical oncology.

[125]  C. Lightdale,et al.  Preoperative endoscopic ultrasound can predict the risk of recurrence after operation for gastric carcinoma. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[126]  J. Ajani,et al.  Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. , 1993, Journal of the National Cancer Institute.

[127]  K. Kohn,et al.  Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. , 1993, Cancer research.

[128]  G. Thompson,et al.  Adenocarcinoma of the stomach: are we making progress? , 1993, The Lancet.

[129]  A. Petroianu,et al.  Modified therapy with 5‐fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer , 1993, Cancer.

[130]  D. Shin,et al.  A phase III randomized study of 5‐fluorouracil and cisplatin versus 5‐fluorouracil, doxorubicin, and mitomycin C versus 5‐fluorouracil alone in the treatment of advanced gastric cancer , 1993, Cancer.

[131]  D. Forman,et al.  An international association between Helicobacter pylori infection and gastric cancer , 1993 .

[132]  C. Boland,et al.  Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. , 1993, Gastroenterology.

[133]  H. Stein,et al.  Comparison of computed tomography, endosonography, and intraoperative assessment in TN staging of gastric carcinoma. , 1993, Gut.

[134]  P. Correa,et al.  Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. , 1992, Cancer research.

[135]  L. Laine,et al.  Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: a University of Southern California pilot program. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[136]  J. Macdonald,et al.  Etoposide in gastric cancer. , 1992, Seminars in oncology.

[137]  D. Lane.  Worrying about p53 , 1992, Current Biology.

[138]  T. Yao,et al.  Pathology and prognosis of gastric carcinoma. Findings in 10,000 patients who underwent primary gastrectomy , 1992, Cancer.

[139]  C. Lightdale,et al.  FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[140]  J. Donohue,et al.  Early gastric cancer , 1992, The Surgical clinics of North America.

[141]  C. V. D. van de Velde,et al.  Quality control of surgical technique in a multicenter, prospective, randomized, controlled study on the surgical treatment of gastric cancer. , 1992, Japanese journal of clinical oncology.

[142]  D. Nagorney,et al.  Correlation of DNA ploidy, histopathology, stage and clinical outcome in gastric carcinoma. , 1992, Surgical oncology.

[143]  B. Vogelstein,et al.  Participation of p53 protein in the cellular response to DNA damage. , 1991, Cancer research.

[144]  J. Monson,et al.  Total gastrectomy for advanced cancer. A worthwhile palliative procedure , 1991, Cancer.

[145]  G. Friedman,et al.  Helicobacter pylori infection and the risk of gastric carcinoma. , 1991, The New England journal of medicine.

[146]  M. Blaser,et al.  Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. , 1991, The New England journal of medicine.

[147]  J. Ajani,et al.  Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy , 1991, Cancer.

[148]  H. Schmoll,et al.  Etoposide, Leukovorin and 5-Fluorouracil (ELF) in Advanced Gastric Carcinoma – Final Results of a Phase-II Study in Elderly Patients or Patients with Cardiac Risk , 1991 .

[149]  Takuma Sasaki,et al.  Expression of C‐erbB‐2 oncoprotein in gastric carcinoma. Immunoreactivity for C‐erbB‐2 protein is an independent indicator of poor short‐term prognosis in patients with gastric carcinoma , 1991, Cancer.

[150]  H. Wieand,et al.  A prospective, randomized evaluation of intensive‐course 5‐fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer , 1991, Cancer.

[151]  M. Buyse,et al.  Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[152]  Wilson Ja.  Perspectives in chemotherapy of advanced gastric cancer. , 1991 .

[153]  J. Fraumeni,et al.  Rising incidence of adenocarcinoma of the esophagus and gastric cardia. , 1991, JAMA.

[154]  N. Viñolas,et al.  Mitomycin C as an adjuvant treatment to resected gastric cancer. A 10-year follow-up. , 1991, Annals of surgery.

[155]  J. Tepper,et al.  Patterns of failure following curative resection of gastric carcinoma. , 1990, International journal of radiation oncology, biology, physics.

[156]  K. Sugimachi,et al.  Persistence of mucosal gastric carcinomas for 8 and 6 years in two patients. , 1990, Archives of pathology & laboratory medicine.

[157]  K. West,et al.  An evaluation of the prognostic significance of HLA‐DR expression in gastric carcinoma , 1990, Cancer.

[158]  E. Rosato,et al.  Adenocarcinoma of the esophagus and esophago-gastric junction: the effects of single and combined modalities on the survival and patterns of failure following treatment. , 1990, International journal of radiation oncology, biology, physics.

[159]  C. McConkey,et al.  Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites. , 1990, British Journal of Cancer.

[160]  D. Amadori,et al.  A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International Collaborative Cancer Group. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[161]  E. Fontham,et al.  Gastric precancerous process in a high risk population: cross-sectional studies. , 1990, Cancer research.

[162]  M. Endo,et al.  Clinical studies of early gastric cancer. , 1990, Hepato-gastroenterology.

[163]  D. Korenaga,et al.  Prognostic significance of dna content with special reference to age in gastric cancer , 1990, Cancer.

[164]  Y. Kato,et al.  Greater tendency for submucosal invasion in fundic area gastric carcinomas than those arising in the pyloric area , 1990, Cancer.

[165]  B. J. Unwin,et al.  The British Society of Gastroenterology early gastric cancer/dysplasia survey: an interim report. , 1990, Gut.

[166]  O. Dalesio,et al.  Adjuvant radiotherapy and chemotherapy in resectable gastric cancer. A randomized trial of the gastro-intestinal tract cancer cooperative group of the EORTC. , 1989, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[167]  M. Sasako,et al.  Lymph node metastases of gastric cancer. General pattern in 1931 patients. , 1989, Annals of surgery.

[168]  W. Allum,et al.  A controlled, prospective, randomised trial of adjuvant chemotherapy or radiotherapy in resectable gastric cancer: interim report. British Stomach Cancer Group. , 1989, British Journal of Cancer.

[169]  J. Siewert,et al.  Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[170]  I. Ellis,et al.  The effect of tamoxifen and estrogen receptor status on survival in gastric carcinoma , 1989, Cancer.

[171]  H. Wilke,et al.  Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[172]  D. Niedzwiecki,et al.  Flow cytometry as a predictive indicator in patients with operable gastric cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[173]  J. Voltas,et al.  Intraoperative and external beam radiotherapy in advanced resectable gastric cancer: technical description and preliminary results. , 1989, International journal of radiation oncology, biology, physics.

[174]  R. Mibu,et al.  Complete ten-year postgastrectomy follow-up of early gastric cancer. , 1989, American journal of surgery.

[175]  H. O. Klein.  Long-term results with FAMTX (5-fluorouracil, adriamycin, methotrexate) in advanced gastric cancer. , 1989, Anticancer research.

[176]  A. Levine,et al.  The p53 proto-oncogene can act as a suppressor of transformation , 1989, Cell.

[177]  K. Hioki,et al.  Strategy for lymphadenectomy of gastric cancer. , 1989, Surgery.

[178]  I. Miyazaki,et al.  Immunohistochemical study of epidermal growth factor and epidermal growth factor receptor in gastric carcinoma , 1989, Cancer.

[179]  J. Samet,et al.  Stomach cancer among New Mexico's American Indians, Hispanic whites, and non-Hispanic whites. , 1989, Cancer research.

[180]  K. Iriyama,et al.  Is extensive lymphadenectomy necessary for surgical treatment of intramucosal carcinoma of the stomach? , 1989, Archives of surgery.

[181]  B. Cady,et al.  Gastric Adenocarcinoma: A Disease in Transition , 1989 .

[182]  K. O'toole,et al.  Increasing incidence and excellent survival of patients with early gastric cancer: experience in a United States medical center. , 1988, The American journal of medicine.

[183]  G. Bonfanti.  Adjuvant treatments following curative resection for gastric cancer , 1988, The British journal of surgery.

[184]  K. Sugimachi,et al.  Dna ploidy is closely linked to tumor invasion, lymph node metastasis, and prognosis in clinical gastric cancer , 1988, Cancer.

[185]  Y. Akine,et al.  Radiation therapy for advanced gastric cancer. , 1988, International journal of radiation oncology, biology, physics.

[186]  B. Henderson,et al.  Diet and high risk of stomach cancer in Shandong, China. , 1988, Cancer research.

[187]  A. Nashimoto,et al.  A statistical evaluation of advancement in gastric cancer surgery with special reference to the significance of lymphadenectomy for cure , 1988, World Journal of Surgery.

[188]  G. Heberer,et al.  Results of gastric resection for carcinoma of the stomach: The European experience , 1988, World Journal of Surgery.

[189]  A. Nakahara,et al.  [Endoscopic therapy of gastrointestinal cancer and its curability]. , 1988, Gan to kagaku ryoho. Cancer & chemotherapy.

[190]  D. Dent,et al.  Randomized comparison of R1 and R2 gastrectomy for gastric carcinoma , 1988, The British journal of surgery.

[191]  P. Hérait,et al.  Phase II trial of combined 5-fluorouracil plus doxorubicin plus cisplatin (FAP regimen) in advanced gastric carcinoma. , 1987, Cancer treatment reports.

[192]  M. Brennan,et al.  Influence of the extent of resection on survival after curative treatment of gastric carcinoma. A retrospective multivariate analysis. , 1987, Archives of surgery.

[193]  W. Macdonald,et al.  Adenocarcinoma of the Esophagus and/or Gastric Cardia , 1987, Cancer.

[194]  J. Tepper,et al.  Analysis of survival and local control following surgery for gastric cancer , 1986 .

[195]  M. Abe,et al.  Intra-operative radiotherapy for carcinoma of the stomach. , 1986, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[196]  C. Willett,et al.  Renal complications secondary to radiation treatment of upper abdominal malignancies. , 1986, International journal of radiation oncology, biology, physics.

[197]  M. O’connell,et al.  A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[198]  J. Fourtillan,et al.  Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[199]  F. di Costanzo,et al.  Randomized comparison of 5-FU alone or combined with carmustine, doxorubicin, and mitomycin (BAFMi) in the treatment of advanced gastric cancer: a phase III trial of the Italian Clinical Research Oncology Group (GOIRC). , 1986, Cancer treatment reports.

[200]  E. Gez,et al.  Combined 5‐fluorouracil (5‐FU) and radiation therapy following resection of locally advanced gastric carcinoma , 1986, Journal of surgical oncology.

[201]  N. Geller,et al.  Adenocarcinoma of the esophagus and gastroesophageal junction. Prognostic factors and results of therapy , 1985, Cancer.

[202]  G. E. Jones,et al.  The relationship between endothelial dysfunction and collagen accumulation in irradiated rat lung. , 1985, International journal of radiation oncology, biology, physics.

[203]  L. Kvols,et al.  A pilot study to determine clinical tolerability of intensive combined modality therapy for locally unresectable gastric cancer. , 1985, International journal of radiation oncology, biology, physics.

[204]  P. Lavin,et al.  Postoperative adjuvant 5‐fluorouracil plus methyl‐CCNU therapy for gastric cancer patients. Eastern cooperative oncology group study (EST 3275) , 1985, Cancer.

[205]  T. Lechevalier,et al.  Chemotherapy and combined modality therapy for locally advanced and metastatic gastric carcinoma. , 1985 .

[206]  Douglass Ho,et al.  Gastric adenocarcinoma--management of the primary disease. , 1985 .

[207]  J. O'fallon,et al.  Combined 5-fluorouracil and radiation therapy as a surgical adjuvant for poor prognosis gastric carcinoma. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[208]  G. Higgins,et al.  Efficacy of prolonged intermittent therapy with combined 5‐FU and methyl‐CCNU following resection for gastric carcinoma. A veterans administration surgical oncology group report , 1983, Cancer.

[209]  C. Mansfield,et al.  Combined nonsimultaneous radiation therapy and chemotherapy with 5-FU, doxorubicin, and mitomycin for residual localized gastric adenocarcinoma: a Southwest Oncology Group pilot study. , 1983, Cancer treatment reports.

[210]  P. Woolley,et al.  Current management of advanced and locally unresectable gastric carcinoma. , 1982, Cancer.

[211]  P. Schein,et al.  A comparison of combination chemotherapy and combined modality therapy for locally advanced gastric carcinoma , 1982, Cancer.

[212]  M. O’connell.  A comparative clinical assessment of combination chemotherapy in the management of advanced gastric carcinoma , 1982, Cancer.

[213]  Mayo,et al.  Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer , 1982, Cancer.

[214]  M. Abe,et al.  Intraoperative radiotherapy: the Japanese experience. , 1981, International journal of radiation oncology, biology, physics.

[215]  K. Sugimachi,et al.  Evaluation of extensive lymph node dissection for carcinoma of the stomach , 1981, World Journal of Surgery.

[216]  Tanaki Kajitani,et al.  The general rules for the gastric cancer study in surgery and pathology , 1981, The Japanese journal of surgery.

[217]  K. Sugimachi,et al.  Critical evaluation of prophylactic splenectomy in total gastrectomy for the stomach cancer. , 1980, Gan.

[218]  C. Gisselbrecht,et al.  5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. , 1980, Annals of internal medicine.

[219]  D. Dalley,et al.  Improved combination chemotherapy in advanced gastric cancer. , 1979, British medical journal.

[220]  W. Wood,et al.  Combined modality treatment of gastric cancer. , 1979, International journal of radiation oncology, biology, physics.

[221]  P. Cheverton,et al.  Prospective randomized trial of combined oncological therapy for gastric carcinoma , 1979, Cancer.

[222]  I. Cohn,et al.  Adenocarcinoma of the stomach: Review of 1,497 cases , 1978, Cancer.

[223]  K. Okajima.  Surgical treatment of gastric cancer with special reference to lymph node removal. , 1977, Acta medica Okayama.

[224]  G. Higgins,et al.  Factors related to survival following resection for gastric carcinoma. Analysis of 903 cases , 1977, Cancer.

[225]  H. Keen,et al.  ORAL HYPOGLYCÆMICS IN DIABETES MELLITUS , 1975, The Lancet.

[226]  S. Carter,et al.  Integration of chemotherapy into combined modality treatment of solid tumors. 1. The overall strategy. , 1974, Cancer treatment reviews.

[227]  Holbrook Ma.  Cancer of the gastrointestinal tract. Radiation therapy. , 1974 .

[228]  J. Kovach,et al.  A controlled study of combined 1,3‐bis‐(2‐chloroethyl)‐1‐nitrosourea and 5‐fluorouracil therapy for advanced gastric and pancreatic cancer , 1974 .

[229]  W. Haenszel,et al.  Stomach cancer among Japanese in Hawaii. , 1972, Journal of the National Cancer Institute.

[230]  K. Kondo,et al.  Histologic criteria of serosal rupture and prognosis in gastric carcinoma , 1972, Cancer.

[231]  W. Dixon,et al.  Use of Triethylenethiophosphoramide as an Adjuvant to the Surgical Treatment of Gastric and Colorectal Carcinoma: Ten‐Year Follow‐up , 1971, Annals of surgery.

[232]  B. Kennedy,et al.  T N M classification for stomach cancer , 1970, Cancer.

[233]  P. Correa,et al.  Carcinoma and intestinal metaplasia of the stomach in Colombian migrants. , 1970, Journal of the National Cancer Institute.

[234]  C. Moertel,et al.  Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. , 1969, Lancet.

[235]  R. Keehn,et al.  Use of 5‐fluorodeoxyuridine (FUDR) as an adjuvant to the surgical management of carcinoma of the stomach , 1969, Cancer.

[236]  V. Gilbertsen,et al.  Results of treatment of stomach cancer. An appraisal of efforts for more extensive surgery and a report of 1,983 cases , 1969, Cancer.

[237]  P. Laurén,et al.  THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. , 1965, Acta pathologica et microbiologica Scandinavica.

[238]  T. Takahashi.  [STUDIES ON PREOPERATIVE AND POSTOPERATIVE TELECOBALT THERAPY IN GASTRIC CANCER. XII]. , 1964, Nihon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica.

[239]  R. Robins,et al.  Local recurrence following subtotal resection for gastric carcinoma. , 1952, Surgery, gynecology & obstetrics.

[240]  S. Truelove,et al.  Carcinoma of the Stomach , 1952, British medical journal.

[241]  L. Bowden,et al.  A CRITICAL EVALUATION OF SUBTOTAL GASTRECTOMY FOR THE CURE OF CANCER OF THE STOMACH , 1951, Annals of surgery.

[242]  J. Tey,et al.  Adjuvant chemoradiotherapy with or without intraoperative radiotherapy for the treatment of resectable locally advanced gastric adenocarcinoma. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[243]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[244]  Kun Yang,et al.  Meta-analysis of effectiveness and safety of D2 plus para-aortic lymphadenectomy for resectable gastric cancer. , 2010, Journal of the American College of Surgeons.

[245]  V. Gebski,et al.  AUSTRALASIAN GASTRO-INTESTINAL TRIALS GROUP. SURVIVAL BENEFI TS FROM NEOADJUVANT CHEMORADIOTHERAPY OR CHEMOTHERAPY IN OESOPHAGEAL CARCINOMA: A META-ANALYSIS , 2007 .

[246]  J. Giedl,et al.  Results of surgical treatment of early gastric cancer in 113 patients , 2005, World Journal of Surgery.

[247]  E. Tahara.  Molecular mechanism of stomach carcinogenesis , 2005, Journal of Cancer Research and Clinical Oncology.

[248]  S. Seeber,et al.  Etoposide, folinic acid, and 5-fluorouracil in carboplatin-pretreated patients with advanced gastric cancer , 2004, Cancer Chemotherapy and Pharmacology.

[249]  A. Tres,et al.  Randomized phase III studies of adjuvant chemotherapy with FAMTX or FEMTX in resected gastric cancer. Pooled results of studies from the EORTC GI-group and the ICCG , 2002 .

[250]  L. Gianni,et al.  Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. , 2002, Tumori.

[251]  Ahmedin Jemal,et al.  Cancer Statistics, 2002 , 2002, CA: a cancer journal for clinicians.

[252]  H. Lippert,et al.  Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[253]  B. Glimelius,et al.  A systematic overview of chemotherapy effects in gastric cancer. , 2001, Acta oncologica.

[254]  J. Donohue,et al.  Results of irradiation or chemoirradiation for primary unresectable, locally recurrent, or grossly incomplete resection of gastric adenocarcinoma. , 2000, International journal of radiation oncology, biology, physics.

[255]  J. Donohue,et al.  Results of irradiation or chemoirradiation following resection of gastric adenocarcinoma. , 2000, International journal of radiation oncology, biology, physics.

[256]  M. Silverstein,et al.  The prognostic significance of amplification and overexpression of c‐met and c‐erb B‐2 in human gastric carcinomas , 2000, Cancer.

[257]  T. Hickish,et al.  Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[258]  N. Willich,et al.  Early results of IORT in the treatment of gastric cancer. , 1997, Frontiers of radiation therapy and oncology.

[259]  J. Zaspel,et al.  Experimental study of vascular sequelae of combined upper abdominal intraoperative and external-beam radiation therapy. , 1997, Frontiers of radiation therapy and oncology.

[260]  T. Wadström.  An update on Helicobacter pylori , 1995 .

[261]  M. Mohiuddin,et al.  Improved local control with adjunctive therapy for cancers of the gastro-esophageal junction , 1994 .

[262]  S. Cha,et al.  Early evaluation of combined fluorouracil and leucovorin as a radiation enhancer for locally unresectable, residual, or recurrent gastrointestinal carcinoma. The North Central Cancer Treatment Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[263]  J. Pignon,et al.  Neoadjuvant chemotherapy in locally advanced gastric carcinoma--a phase II trial with combined continuous intravenous 5-fluorouracil and bolus cisplatinum. , 1994, European journal of cancer.

[264]  D. Cunningham,et al.  Chemotherapy of carcinoma of the stomach. , 1993, Cancer treatment reviews.

[265]  H. Yokozaki,et al.  Growth Factors in Gastric Cancer , 1993 .

[266]  P. Romestaing,et al.  [Intraoperative radiotherapy in gastric adenocarcinomas. Apropos of 45 cases]. , 1993, Annales de chirurgie.

[267]  F. Cavalli,et al.  Taxotere is active in advanced gastric carcinoma: Results of a phase II clinical trial , 1993 .

[268]  J. Tepper,et al.  Randomized trial of intraoperative radiotherapy in carcinoma of the stomach. , 1993, American journal of surgery.

[269]  W. Regine,et al.  Impact of adjuvant therapy on locally advanced adenocarcinoma of the stomach. , 1992, International journal of radiation oncology, biology, physics.

[270]  F. Calvo,et al.  Intraoperative and external radiotherapy in resected gastric cancer: updated report of a phase II trial. , 1992, International journal of radiation oncology, biology, physics.

[271]  V. V. Kremlev,et al.  [Results of combined treatment of cancer of the gastric antrum and gastric body]. , 1990, Voprosy onkologii.

[272]  Kossé Va.  Combined treatment of gastric cancer using hypoxic radiotherapy , 1990 .

[273]  K. Kern.  Gastric cancer: A neoplastic enigma , 1989, Journal of surgical oncology. Supplement.

[274]  L. Gunderson,et al.  Gastrointestinal tract radiation tolerance. , 1989, Frontiers of radiation therapy and oncology.

[275]  D. Coit,et al.  Radical surgery for gastric cancer. A review of the Japanese experience , 1989, Cancer.

[276]  M. Schemper,et al.  The effect of adjuvant chemotherapy in gastric carcinoma is dependent on tumor histology: 5-year results of a prospective randomized trial. , 1988, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[277]  W. Meyers,et al.  Adenocarcinoma of the stomach. Changing patterns over the last 4 decades. , 1987 .

[278]  E. Evans,et al.  Factors influencing prognosis in gastric cancer. , 1987, The Australian and New Zealand journal of surgery.

[279]  A. Russell,et al.  Adenocarcinoma of the stomach: autopsy observations with therapeutic implications for the radiation oncologist. , 1986, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[280]  L. Gunderson,et al.  Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. , 1982, International journal of radiation oncology, biology, physics.

[281]  J. Fortner,et al.  Local recurrence of gastric adenocarcinomas after gastrectomy , 1981, Journal of surgical oncology.

[282]  M. Abe,et al.  Clinical experiences with intraoperative radiotherapy of locally advanced cancers , 1980, Cancer.

[283]  J. Bingham.  Letter: Lower oesophageal sphincter. , 1974, Lancet.

[284]  R. Borrmann.  Geschwülste des Magens und Duodenums , 1926 .